An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis

S Genevay, G Hayem, P Verpillat, O Meyer

**Objectives**: Antikeratin antibodies (AKA) and antiperinuclear factor (APF) are specific antibodies found very early in rheumatoid arthritis (RA). The objective of this eight year follow up study was to assess the value of early AKA and APF assays in predicting functional disability and cartilage damage.

**Method**: In 2000, 64 patients tested for AKA and APF (antifilaggrin antibodies) between 1990 and 1993 during evaluation of early symmetric oligoarthritis or polyarthritis (suspected RA) were invited to participate in this non-concurrent cohort study. The Health Assessment Questionnaire (HAQ) score, disease activity score (DAS), and Larsen radiographic score were the primary evaluation criteria.

**Results**: Twenty nine patients were re-evaluated. Clinical and laboratory data obtained in 1993 were similar in this group and in the 35 other patients. Twenty five patients had received a diagnosis of RA. Nine (31%) were rheumatoid factor (RF) positive, nine (31%) were AKA positive, and six (21%) were APF positive during the first year of the disease. APF was correlated with the Larsen score ($p=0.011$) and DAS ($p=0.035$) evaluated after a mean disease duration of 8.55 years. All APF positive patients had erosive disease. AKA was correlated with the DAS ($p=0.035$).

**Conclusion**: The presence of AKA or APF early in the course of RA was associated with the DAS or Larsen score eight years later. The number of patients was small, but the findings confirmed those of studies with shorter follow ups.

**Patients and Methods**

**Patients**
The study extended data from a cohort study on early polyarthritis conducted in the early 1990s. In 1993, two years after enrolment of 64 consecutive patients with early polyarthritis, 49 (77%) patients met the American College of Rheumatology (ACR) criteria for RA and 15 (23%) were considered to have undifferentiated polyarthritis. In 2000, extensive efforts were made to re-evaluate all 64 patients. Twenty nine patients agreed to undergo a full clinical, laboratory, and radiological evaluation (see fig 1 for reasons for drop out).

**Methods**
The clinical diagnosis of RA was reassessed. Extra-articular features, criteria for remission according to the American Rheumatism Association (ARA)/ACR, and the number of disease modifying drugs used were recorded. The disease activity score (DAS) was calculated. Patients with a DAS score lower than 1.6 were classified as “in remission according to DAS”.

The HLA generic type and the DRB1*01 and DRB1*04 subtypes were determined. Each patient completed a generic quality of life questionnaire (HAQ).

Radiographs of both hands and feet were read by two of us (SG and GH) and scored according to a modified version of the

**Abbreviations**: ACR, American College of Rheumatology; APF, antiperinuclear factor; AKA, antikeratin antibodies; DAS, disease activity score; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor; SSOs, sequence specific oligonucleotides
Larsen score, the values of which can range from 0 to 160. Before the readings, a cut off was set at 5 to account for minor irregularities: patients whose score was lower than 5 were classified as having “non-erosive disease” and patients with a score of 5 or more as having “erosive disease”.

Primary outcome measures were the DAS, HAQ score, and Larsen score.

Laboratory test methods
Blood specimens for determination of APF, AKA, and RF were obtained at study entry (between 1990 and 1993). AKA IgGs were sought using indirect immunofluorescence as described by Young et al., with a few modifications; serum samples were diluted 1/20. APF IgG were detected using indirect immunofluorescence on human buccal cells; serum samples were diluted to 1/40 to improve specificity and considered positive if diluted 1/20. APF IgG were detected using indirect immunofluorescence on human buccal cells; serum samples were diluted to 1/40 to improve specificity and considered positive if diluted 1/20.

Statistical methods
Statistical analyses were conducted with SAS software (release 8.0; SAS Institute Inc, Raleigh, NC, USA). Between observer agreement for determination of Larsen score determination was high (r=0.956, p<0.001), we used the mean of the two determinations. The scores ranged from 0 to 51 (mean, 10.5 (SD 14.95)). Twelve patients had a Larsen score greater than 5, defining erosive disease; of the 13 other patients, four had scores between 1 and 4 and nine had a score of 0.

Patients who were APF positive early on had more severe disease eight years later, as shown by the higher DAS score (3.98 (95% confidence interval (95%CI) 2.18 to 5.78) v 2.26 (95%CI 1.71 to 2.810; p=0.009, fig 2) and Larsen score (22.5 (95%CI 18.56 to 39.14) v 6.71 (95%CI 5.52 to 12.90); p=0.02). Patients who were AKA positive at study entry had a higher DAS (3.75 (95%CI 2.30 to 5.20) v 2.16 (95%CI 1.63 to 2.68); p=0.009) and a non-significantly higher Larsen score (15.22 v 7.84; p=0.24) (table 1). All APF positive patients were in the erosive disease group; half the patients with erosive disease were positive for either APF or AKA early in the disease; the difference was significant.

None of the three scores (DAS, Larsen, HAQ) were statistically correlated with presence of RF early in the disease, although a trend was seen for DAS (p=0.08). Female sex predicted absence of remission (p=0.027 by univariable analysis), with women having an odds ratio of 10.67 (1.31–86.93) compared with men. Nevertheless, sex did not affect the associations between serological markers and primary evaluation criteria (data not shown).

DISCUSSION
This eight year prospective cohort study found a correlation linking baseline APF positive patients with severity of joint inflammation (86%) had a definite diagnosis of RA in 2000 and were entered in the analyses reported below. Their mean age at onset of RA was 30.6 (SD 15.5) years (range, 18.9–7.2) and mean follow up was 8.5 (SD 0.64) years (range, 7.2–9.9).

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>DAS</th>
<th>HAQ</th>
<th>Larsen</th>
</tr>
</thead>
<tbody>
<tr>
<td>APF Positive</td>
<td>2.26 (p = 0.035)</td>
<td>0.75 (NS)</td>
<td>6.71 (p = 0.01)</td>
</tr>
<tr>
<td>AKA Positive</td>
<td>3.98 (p = 0.035)</td>
<td>0.94 (p = 0.011)</td>
<td>22.50 (NS)</td>
</tr>
<tr>
<td>RF Positive</td>
<td>3.75 (p = 0.035)</td>
<td>0.82 (NS)</td>
<td>15.22 (NS)</td>
</tr>
<tr>
<td>APF Negative</td>
<td>2.16 (p = 0.78)</td>
<td>0.78 (NS)</td>
<td>6.71 (p = 0.12)</td>
</tr>
<tr>
<td>AKA Negative</td>
<td>3.33 (NS)</td>
<td>0.78 (NS)</td>
<td>14.61 (NS)</td>
</tr>
<tr>
<td>RF Negative</td>
<td>3.33 (NS)</td>
<td>0.78 (NS)</td>
<td>14.61 (NS)</td>
</tr>
</tbody>
</table>

**Figure 2** (A) Distribution of DAS values in APF negative (APF 0), APF positive (APF 1), AKA negative (AKA 0), and AKA positive (AKA 1) patients. Box plots represent the lower quartile, the median, and the upper quartile. Extremities of lines indicate the 10th and 90th percentiles. The points are the extreme values, below the 10th centile or above the 90th centile. The p values are given for each statistical analysis. (B) Same representation as for Larsen score. NS, non-significant.
destruction and clinical RA activity. Moreover, all APF positive patients were classified in the erosive disease group. Patients who were AKA positive at baseline had more active disease, confirming the close association between APF and AKA antibodies.

Few longitudinal studies on associations linking APF or AKA to RA severity have been published. Some short term studies found that AKA was correlated with clinical indices but not with Larsen score,\(^1\)\(^2\) whereas others found the opposite.\(^1\)\(^3\) In a long term study of APF and AKA, Kurki et al found no association linking these antibodies to severity of erosions.\(^1\)\(^3\) Nevertheless, all AKA positive and 98% of APF positive patients presenting with polyarthritis had erosive disease after eight years. A more recently published three year study of APF\(^1\)\(^4\) found results very similar to ours. Interestingly, the same correlation was found for anticitrullinated cyclic peptide (anti-CCP) antibodies, which have been shown to recognize both perinuclear factor and (pro)-filaggrin.\(^1\)\(^5\)

Surprisingly, RF was not associated with any of the study indices. Possible explanations include the very early time of serological marker determination and the limited statistical power of the study related to the few patients. However, this finding suggests that, in patients with very early RA, determination of APF/AKA may supply additional information on the risk of unfavourable outcomes.

In conclusion, although limited by the few patients, this study is the first to investigate associations between APF/AKA in patients with early RA and several aspects of RA severity evaluated eight years later. The associations with disease activity and with the Larsen score accord with most published longitudinal studies. Our data indicate that these autoantibodies provide additional information to clinicians and, consequently, should be added to the list of initial tests in patients with early RA.

Authors’ affiliations
S Genevay, G Hayem, O Meyer, Rheumatology Department, Bichat-Claude Bernard Teaching Hospital, 46 rue Henri Huchard, 75018 Paris, France
P Verpillat, Biostatistics and Epidemiology Department

Correspondence to: Professor O Meyer, Hôpital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France; olivier.meyer@bch.ap-hop-paris.fr

Accepted 4 March 2002

REFERENCES


An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis
S Genevay, G Hayem, P Verpillat and O Meyer

Ann Rheum Dis 2002 61: 734-736
doi: 10.1136/ard.61.8.734

Updated information and services can be found at:
http://ard.bmj.com/content/61/8/734

These include:

References
This article cites 14 articles, 4 of which you can access for free at:
http://ard.bmj.com/content/61/8/734#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)
Epidemiology (1384)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/